The latest from small and Emerging Pharma companies featuring Angelini Pharma, Generate:Biomedicines and Quiver Bioscience. 

For news on the large and mid-sized bio/pharmaceutical companies, see Global Briefs. 

* Angelini Pharma, Quiver Bioscience in Research & Licensing Pact for Genetic Epilepsies 
* Generate:Biomedicines Files IPO 

---

Angelini Pharma, Quiver Bioscience in Research & Licensing Pact for Genetic Epilepsies 
Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience, a company advancing programs for the treatment of central nervous system (CNS) disorders, have entered into a collaboration and licensing agreement to advance therapeutics for genetic epilepsies. The collaboration brings together Quiver’s drug-discovery capabilities, data assets, and AI models with Angelini Pharma’s expertise in brain health and epilepsy drug development. Under the multi-year agreement, Quiver will receive an undisclosed advance payment and support for defined research activities along with additional licensing fees granting Angelini Pharma exclusive access to collaboration-generated data during the research term. Quiver is also eligible to receive additional milestones payments of up to $120 million and additional royalties upon Angelini’s election of drug targets identified through the collaboration. 

Source: Angelini Pharma  

---

Generate:Biomedicines Files IPO 
Generate:Biomedicines, a Somerville, Massachusetts-based bio/pharmaceutical company applying a proprietary system applying AI and machine learning to design and optimize proteins for therapeutic applications, with a focus on immunology, oncology, and infectious diseases, has filed an initial public offering to list its shares on Nasdaq. The company has successfully progressing three computationally engineered proteins into human clinical testing, the most advanced of which is GB-0895, an investigational long-acting anti-thymic stromal lymphopoietin monoclonal antibody, in Phase III clinical trials for severe asthma. The company says it also expects to advance two additional computationally generated oncology product candidates into Phase I clinical trials in 2026. 

 Its lead candidate is GB-0895, an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma. 

Source: Generate:Biomedicines